Cathepsins and osteosarcoma: Expression analysis identifies cathepsin K as an indicator of metastasis

Molecular Carcinogenesis

Volumn 47, Issue 1, 2008, Pages 66-73

  Husmann, Knut ^a   Muff, Roman ^a   Bolander, Marc E ^b   Sarkar, Gobinda ^b   Born, Walter ^a   Fuchs, Bruno ^a,b  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

^b MAYO CLINIC   (United States)

Author keywords

Molecular marker; Protease; Survival

Indexed keywords

BIOLOGICAL MARKER; CATHEPSIN D; CATHEPSIN F; CATHEPSIN H; CATHEPSIN K; CATHEPSIN L; CATHEPSIN V; MESSENGER RNA; CATHEPSIN; CYSTEINE PROTEINASE; PRIMER DNA;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UPREGULATION; BONE TUMOR; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY;

BONE NEOPLASMS; CATHEPSIN D; CATHEPSINS; CYSTEINE ENDOPEPTIDASES; DNA PRIMERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM METASTASIS; OSTEOSARCOMA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 38349023103     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20362     Document Type: Article

References (43)

1. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop ReI Res 2002;397:40-52.
2. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004;9:422-441.
3. Khanna C, Hunter K. Modeling metastasis in vivo. Carcinogenesis 2005;26:513-523.
4. Decock J, Paridaens R, Cufer T. Proteases and metastasis: Clinical relevance nowadays? Curr Opin Oncol 2005;17: 545-550.
5. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. J Pathol 2003;200:465-470.
6. Sternlicht MD, Werb Z. How matrix metalloproteinases regulate cell behaviour. Annu Rev Cell Biol 2001;17:463-516.
7. Gocheva V, Zeng W, Ke D, et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev 2006;20:543-556.
8. Mohamed MM, Sloane BF. Cysteine cathepsins: Multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764-775.
9. Skrzydlewska E, Sulkowska M, Koda M, Sulkowski S. Proteolytic- antiproteolytic balance and its regulation in carcinogenesis. World J Gastroenterol 2005;11:1251-1266.
10. Rawlings ND, Morton FR, Barrett AJ. MEROPS: The peptidase database. Nucleic Acids Res 2006;34:D270-272.
11. Turk V, Turk B, Guncar G, Turk D, Kos J. Lysosomal cathepsins: Structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul 2002;42: 285-303.
12. Liaudet-Coopman E, Beaujouin M, Derocq D, et al. Cathepsin D: Newly discovered functions of a long-standing aspartic protease in cancer and apoptosis. Cancer Lett 2006;237:167-179.
13. Fehrenbacher N, Jaattela M. Lysosomes as targets for cancer therapy. Cancer Res 2005;65:2993-2995.
14. Laurent-Matha V, Maruani-Herrmann S, Prebois C, et al. Catalytically inactive human cathepsin D triggers fibroblast invasive growth. J Cell Biol 2005;168:489-499.
15. Premzl A, Puizdar V, Zavasnik-Bergant V, et al. Invasion of ras-transformed breast epithelial cells depends on the proteolytic activity of cysteine and aspartic proteinases. Biol Chem 2001;382:853-857.
16. Haeckel C, Ayala AG, Radig K, Raymond AK, Roessner A, Czerniak B. Protease expression in dedifferentiated parosteal osteosarcoma. Arch Pathol Lab Med 1999;123:213-221.
17. Krueger S, Haeckel C, Buehling F, Roessner A. Inhibitory effects of antisense cathepsin B cDNA transfection on invasion and motility in a human osteosarcoma cell line. Cancer Res 1999;59:6010-6014.
18. Krueger S, Kellner U, Buehling F, Roessner A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: Effects on the invasive phenotype. Cancer Gene Ther 2001;8:522-528.
19. Park IC, Lee SY, Jeon DG, et al. Enhanced expression of cathepsin L in metastatic bone tumors. J Korean Med Sci 1996;11:144-148.
20. Jia SF, Worth LL, Kleinerman ES. A nude mouse model of human osteosarcoma lung metastases for evaluating new therapeutic strategies. Clin Exp Metastasis 1999;17:501-506.
21. Worth LL, Jia S-F, Zhou Z, Chen L, Kleinerman ES. Intranasal therapy with an adenoviral vector containing the murine interleukin-12 gene eradicates osteosarcoma lung metastases. Clin Cancer Res 2000;6:3713-3718.
22. Lafleur E, Koshkina NV, Stewart J, et al. Increased fas expression reduces the metastatic potential of human osteosarcoma cells. Clin Cancer Res 2004;10:8114-8119.
23. Unni KK. Dahlin's Bone Tumors: General aspects on 11,087 cases. Philadelphia: Lippincott-Raven Publishers; 1996. 463p.
24. Kumar R, Schaefer J, Grande JP, Roche PC. Immunolocalization of calcitriol receptor, 24-hydroxylase cytochrome P-450, and calbindin D28k in human kidney. Am J Physiol 1994;266: F477-485.
25. Srivastava A, Fuchs B, Zhang K, et al. High WT1 expression is associated with very poor survival of patients with osteogenic sarcoma metastasis. Clin Cancer Res 2006;12:4237-4243.
26. Lindeman JH, Hanemaaijer R, Mulder A, et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am J Pathol 2004;165:593-600.
27. Chen G, Gharib TG, Huang CC, et al. Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 2002;1:304-313.
28. Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, et al. Overexpression of cathepsin F, matrix metalloproteinases 11 and 12 in cervical cancer. BMC Cancer 2005;5:68.
29. Frohlich E, Schlagenhauff B, Mohrle M, Weber E, Klessen C, Rassner G. Activity, expression, and transcription rate of the cathepsins B, D, H, and L in cutaneous malignant melanoma. Cancer 2001;91:972-982.
30. Schweiger A, Christensen IJ, Nielsen HJ, Sorensen S, Brunner N, Kos J. Serum cathepsin H as a potential prognostic marker in patients with colorectal cancer. Int J Biol Markers 2004;19: 289-294.
31. Staack A, Tolic D, Kristiansen G, Schnorr D, Loening SA, Jung K. Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. Urology 2004;63:1089-1094.
32. Frohlich E, Möhrle M, Klessen C. Cathepsins in basal cell carcinomas: Activity, immunoreactivity and mRNA staining of cathepsins B, D, H and L. Arch Dermatol Res 2004;295: 411-421.
33. Nishimura Y, Kato K. Identification of latent procathepsin H in microsomal lumen: Characterization of proteolytic processing and enzyme activation. Arch Biochem Biophys 1988; 260:712-718.
34. Klose A, Zigrino P, Dennhofer R, Mauch C, Hunzelmann N. Identification and discrimination of extracellularly active cathepsins B and L in high-invasive melanoma cells. Anal Biochem 2006;353:57-62.
35. Vasiljeva O, Papazoglou A, Kruger A, et al. Tumor cell-derived and macrophage-derived cathepsin B promotes progression and lung metastasis of mammary cancer. Cancer Res 2006;66:5242-5250.
36. Kawasaki G, Kato Y, Mizuno A. Cathepsin expression in oral squamous cell carcinoma: Relationship with clinicopathologic factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2002;93:446-454.
37. Vigneswaran N, Zhao W, Dassanayake A, Muller S, Miller DM, Zacharias W. Variable expression of cathepsin B and D correlates with highly invasive and metastatic phenotype of oral cancer. Hum Pathol 2000;31:931-937.
38. Chauhan SS, Goldstein U, Gottesman MM. Expression of cathepsin L in human tumors. Cancer Res 1991;51:1478-1481.
39. Yamaza T, Goto T, Kamiya T, Kobayashi Y, Sakai H, Tanaka T. Study of immunoelectron microscopic localization of cathepsin K in osteoclasts and other bone cells in the mouse femur. Bone 1998;23:499-509.
40. Mandelin J, Hukkanen M, Li TF, et al. Human osteoblasts produce cathepsin K. Bone 2006;38:769-777.
41. Brubaker KD, Vessella RL, True LD, Thomas R, Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 2003;18:222-230.
42. Dhaini HR, Thomas DG, Giordano TJ, et al. Cytochrome P450 CYP3A4/5 expression as a biomarker of outcome in osteosarcoma. J Clin Oncol 2003;21:2481-2485.
43. Hoang BH, Kubo T, Healey JH, et al. Expression of LDL receptor-related protein 5 (LRP5) as a novel marker for disease progression in high-grade osteosarcoma. Int J Cancer 2004;109:106-111.